HR 1.93, 95% Confidence Interval 1.01-3.68 compared to the lower tertiles). However, this association was attenuated and no longer significant in multivariate analyses.
Conclusions: Levels of primary BAs were reduced and specific secondary BAs increased in patients with chronic HF. This pattern was associated with reduced overall survival in univariate analysis, but not in multivariate analyses. Future studies should assess the regulation and potential role of BA metabolism in HF. 
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Introduction
Heart failure (HF) is a major public health issue with increasing prevalence due to an aging population and improved management of the disease 1 . However, the mortality and morbidity of HF are still high, at least partly reflecting the possibility that important pathogenic mechanisms are not targeted by the current therapeutic options 2 . Metabolic and inflammatory disturbances have been suggested to play a role in the development and progression of chronic HF 3 , but these issues remain far from clear.
Research over the last decades has expanded the traditional view of bile acids (BAs) beyond their role in cholesterol elimination and emulsification of dietary fat. BAs are now recognized as signaling molecules that interact with both plasma membrane and nuclear receptors, exerting regulatory effects on glucose and lipid metabolism 4 , energy homeostasis 5 and other physiological processes 6 . We have recently reported decreased ratio of 12αhydroxylated/non 12α-hydroxylated BA six months after bariatric surgery 7 , associated with an improvement in insulin sensitivity and downregulation of inflammatory responses 8 .
Emerging evidence suggests that BAs may also play a role in regulating cardiovascular function. In the heart and systemic circulation, BAs interact with plasma membrane Gprotein coupled receptors, e.g. TGR5, and nuclear receptors, e.g. the farnesoid (FXR) and pregnane/steroid and xenobiotic receptors (PXR/SXR) (9) . It has been suggested that BAs reduce heart rate by regulating channel conductance and calcium dynamics in sino-atrial and ventricular cardiomyocytes, and regulate vascular tone via both endothelium-dependent andindependent mechanisms 10 . Hence, a potential role of BAs in cardiovascular disease has been proposed.
The gastrointestinal tract contains a dynamic microbial community, denoted the gut microbiota. Altered gut microbiota has been linked to diseases associated with chronic systemic inflammation and metabolic disturbances such as obesity, type 2 diabetes mellitus 11 and cardiovascular disease 12 
Material and Methods
Patients
The study population has previously been described in details 17 . In brief, a total of 142 patients with HF for >6 months, stabilized on state-of-art treatment for at least 3 months, were consecutively included in a prospective cohort study at the Department of Cardiology, Oslo University Hospital Rikshospitalet, Oslo, Norway ( Table 1) 
Blood sampling and biochemistry
For measurement of primary BAs, secondary BAs and their conjugated (glycine and taurine) fractions, we collected peripheral venous blood in pyrogen-free tubes with EDTA as anticoagulant. The samples were non-fasting, drawn after a light, standard Norwegian breakfast. The tubes were immediately immersed in melting ice and centrifuged within 30 minutes at 2,000g for 20 minutes to obtain platelet-poor plasma. All samples were stored at -80ºC until analysis and thawed <three times. BAs analyses were performed using liquid chromatography tandem mass spectrometry (LC-MS/MS) by an established in-house assay 18 . 
Right-sided heart catheterization
Right-sided heart catheterization was performed using a Swan-Ganz pulmonary artery thermodilution catheter (Baxter Health Care Corp, Santa Ana, CA, USA). Right heart haemodynamics were recorded, and cardiac output was measured using the thermodilution technique.
Echocardiography
Echocardiography was performed using Vivid 7 or E9 ultrasound scanners (GE Vingmed Ultrasound, Horten, Norway), with phased array transducers. Cine loops were digitally stored and analyzed offline using ECHO-PAC software (GE Vingmed Ultrasound). Twodimensional parameters and conventional Doppler measurements were recorded according to current recommendations. Left ventricular ejection fraction (LVEF) was measured using
Simpson's biplane method.
Statistical analysis
Differences between groups were analyzed with the use of 
Results
Clinical characteristics
Clinical characteristics are provided in Table 1 . The healthy control subjects were matched for age and gender, and had no previous MI, hypertension or diabetes, or concurrent medication. There were significantly higher eGFR measurements and fewer smokers among the controls. Furthermore, there was a tendency to higher BMI in HF patients, although it should be noted that BMI was available from only half the control subjects.
Altered bile acid composition in HF patients
As shown in Figure 1A and Supplementary Table, levels of primary BAs were significantly lower in patients with HF than in controls. This difference was mainly driven by lower levels of chenodeoxycholic acid (CDC) and its glycine (GCDC) and taurine (TCDC) conjugates, as well as the glycine conjugate of cholic acid (GCA) in patients with HF.
In the gut, glycine-conjugated and taurine-conjugated BAs are deconjugated by bacterial bile salt hydrolases. Primary BAs are subsequently dehydroxylated to secondary BAs by bacterial 7-alpha-dehydroxylases (i.e., CA is converted to deoxycholic acid (DC) and CDC to lithocholic acid [LC]). Reabsorbed BAs are further conjugated to glycine and taurine in the liver. Notably, in parallel with the observed reduction in GCDC (and numerically also CDC and TCDC), there was an increase in LC (p=0.001) and its conjugates GLC (p<0.001) and TLC (p<0.001) in patients with chronic HF. Finally, the glycine conjugate of ursodeoxycholic acid (GUDC) was also increased (p=0.001) in these patients ( Figure 1A) . 
Increased secondary/primary BA-ratio in chronic heart failure patients
Our findings so far suggested that in HF, there were decreased levels of primary BAs and increased levels of specific secondary BAs. Indeed, the ratio of secondary to primary BAs was significantly higher in patients with HF than in healthy control subjects ( Figure 1B ).
Adjusting for eGFR and current smoking in a linear regression model, the difference in BAratio between HF patients and controls was still significant (p<0.001).
There was a higher proportion of patients with hypertension and use of β-blockers with higher tertiles of the secondary/primary BA-ratio, but this ratio was not associated with other baseline characteristics outlined in Table 1 such as age, renal function, New York Heart Association (NYHA) class, LVEF, NT-proBNP or CRP.
Association between the individual BAs and NT-proBNP as well as potential determinants including renal function, liver function, glycemic control and albumin are presented in Table   2 . NT-proBNP correlated positively with the primary BAs TCDC and TCA and negatively with the secondary BA DC, but not with total primary or secondary BAs. The secondary BA LC was negatively correlated with eGFR. The primary BAs GCA and TCA, as well as total primary BAs and the secondary BA GUDC were correlated with ALT. None of the BAs were associated with HbA1c. Finally, the taurine-conjugated primary BAs TCDC and TCA were negatively correlated with albumin.
Association with pulmonary artery pressure and plasma lipopolysaccharide 
Discussion
The main findings in this study can be summarized as follows: i) Levels of primary BAs were lower and levels of specific secondary BAs were higher in patients with HF than in healthy control subjects, resulting in an increased secondary to primary BA ratio in HF, ii) an increased ratio of secondary to primary BAs tended to be associated with reduced overall survival on univariate analysis, but this association was not significant after adjustment for clinical characteristics and NT-proBNP.
BAs have been shown to have effects on the cardiovascular system including interaction with endothelial function, heart rate and various metabolic pathways at least partly involving signaling through nuclear and plasma membrane receptors 10 The present study is, to the best of our knowledge, the first to assess a wide range of BAs in HF patients, observing reduced levels of multiple primary BAs in HF patients compared with healthy controls, while several of the secondary BAs, were higher. Although the formation of secondary BAs is dependent on transformation of primary BAs by intestinal bacteria 15 , several factors could influence the secondary to primary BA ratio. In this context, one could argue that our observations are possibly just an epiphenomenon of cardiac congestion that affects patients with HF. However, data obtained from right heart catheterization of these patients showed a modest negative correlation with pulmonary artery pressures, refuting this hypothesis. Furthermore, there was a modest, but positive correlation between plasma levels of secondary BAs and lipopolysaccharide in the patients, suggesting that an increased microbial activity could contribute to some of the observations in this study.
Although an increased ratio of secondary to primary BAs tended to be associated with reduced overall survival in univariate analysis, this association was no longer significant after adjustment for NT-proBNP. The negative association between the BA-ratio and pulmonary artery pressures further weakens the argument that this ratio has an independent prognostic value in HF. However, it should be noted that the current study was an exploratory rather than a prognostic study, and larger, independent samples are needed to evaluate secondary to primary BAs in relation to clinical end points.
Individual BAs have highly variable agonist activity and affinity to the proposed target receptors in the heart 20 and a reasonable hypothesis is therefore that specific BAs could be more distinctly associated with outcome. Notably, none of the primary or secondary BAs alone were associated with reduced survival, suggesting that the metabolism of BAs, rather than BAs per se may play a role in chronic HF. The levels of circulating BAs, however, are low and subject to large inter-individual variation 21 , and given the moderate sample size of our study, the low number of clinical events and the single time-point blood draw, there is therefore a risk of underestimating the potential effect of individual BAs. In particular, the potent effect of the secondary bile acid LC (elevated in HF) on the bile acid receptor TGR5, expressed in the heart, could have physiological consequences not detected in the present study 22 . On the other hand, it was recently reported from a mouse model that an elevated level of total serum BA could contribute to liver-associated cardiac dysfunction, possibly due to impaired cardiac fatty acid oxidation, suggesting the involvement of the total BA pool, rather than individual BAs in HF 23 .
In addition to gut microbiota dependent conversion from primary to secondary BAs, other factors influencing the production, metabolism and clearance of individual BAs could have affected the secondary/primary BA ratio. First, it should be noted that this ratio was driven by higher levels of some secondary BAs, and lower levels of some primary BAs, and does not necessarily reflect an increased global transformation from primary to secondary BAs in HF.
Although dietary habits of the study population were not controlled for, we observed that the taurin conjugated primary BAs TCDC and TCA were negatively correlated with albumin.
Furthermore, the primary BAs GCA and TCA, as well as total primary BAs were correlated with ALT. Hence, protein malnutrition and liver congestion could both could be associated with higher levels of primary BAs in some patients, which could have reduced rather than amplified the secondary/primary BA ratio in HF patients. Furthermore, although BAs may interact with glucose metabolism and energy homeostasis 4,5 , none of the individual BAs were associated with glycemic control as measured by HbA1c. Finally, with the exception of a negative correlation between the secondary BA LC and eGFR, levels of BAs did not seem to be influenced by renal clearance, and the difference in BA ratio between HF patients and controls remained significant after adjustment for eGFR and current smoking.
Factors influencing the gut microbiota could also have affected our results. Although none of the patients used antibiotics at the time of blood collection, we do not have data on the use of antibiotics in the period before hospitalization, and these medications can perturb the gut microbiota, resulting in failure of the BA dehydroxylation necessary for the formation of secondary BAs. Another limitation is lack of BMIs in half of the control subjects, although the BA ratio was not associated with BMI in the HF patients. Moreover, relatively few patients were included and the number of fatal events during follow-up was also low. Finally, this is a purely descriptive study and at present no conclusion can be drawn on causes and consequences of the disturbed BA metabolism in HF.
In conclusion, levels of primary BAs were reduced and specific secondary BAs increased in patients with chronic HF. Although this pattern was associated with reduced overall survival in univariate analysis, this association was lost in multivariate analyses. Future studies should thoroughly assess the potential role of the BA composition in patients with HF, and investigate whether manipulation of factors influencing BA metabolism, including the intestinal microbial community, could alter clinical outcome.
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